Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT-6000
- Development stage
- Unknown
- Lead developer
- RenaissThera
- Modality
- Small Molecules
01
Overview
RT-6000 is an investigational small molecule agonist of the apelin receptor (APLNR) being developed by RenaissThera. It is targeted toward the treatment of metabolic disorders, specifically Type 2 Diabetes Mellitus and obesity. The apelin signaling system is a key regulator of cardiovascular and metabolic homeostasis; activation of the apelin receptor has been shown to improve insulin sensitivity and glucose utilization in peripheral tissues. According to company pipeline information, RT-6000 is currently in Phase 2 clinical development. However, external verification of this candidate and the developer RenaissThera is limited, and internal context suggests the pipeline data may be fabricated.
02
Targets
APLNR (Apelin receptor)
Beyond the preview
Go deeper on RT-6000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT-6000.